ONE life sciences network event

The next ONE Life Sciences network event in Aberdeen, on 30 October 2018, will focus on communicating success, exploring how profile raising, marketing and stakeholder engagement can support company creation and growth.

The speakers are Dr Caroline Barelle, CEO of Aberdeen-based biologics developer Elasmogen, and Alix Mackay, a Glasgow-based specialist in life sciences and healthcare marketing.

The session will include presentations, Q&A and networking. A light supper will be provided.

Dr Barelle founded Elasmogen in 2016 and has rapidly established the company as a global biotech with an international profile and late-stage, pre-clinical products positioned to make a sight-saving difference in ophthalmology. Dr Barelle has secured collaborative partnerships with companies that include Almac Discovery Ltd and the US bio-pharmaceutical giant, Amgen Inc. She was the winner in the Rising Stars: Extraordinary Talent category at Scotland’s Life Sciences Dinner & Annual Awards 2017.

Alix Mackay works with business leaders and marketers in life sciences, biotechnology and healthcare. She combines 14 years of big pharma marketing and sales discipline with the latest best practice in online marketing to provide advice, bespoke strategy and masterclasses. Alix also co-leads the Life Sciences Scotland marketing and communications group, is an associate member of IBioIC and a member of the Royal Society of Chemistry.

More information and booking is available at https://www.eventbrite.co.uk/e/one-life-sciences-network-event-tickets-50217340417.

ONE Life Sciences, the sector board of North East Scotland’s private sector led and funded economic development company Opportunity North East, aims to build a vibrant cluster of life sciences companies in the region, capitalising on the established triple helix of researchers, clinicians and companies centred on the Foresterhill Health Campus in Aberdeen and the sector’s proven strengths, which include biologics, health data science, drug discovery and medtech. The sector target is to double the size of the company base by 2027.

Working with partners, including the University of Aberdeen, Robert Gordon University and NHS Grampian, to create links between academics, clinicians and companies to build the cluster network and its ambition are strategic priorities for ONE Life Sciences.